Arase Yasuji, Suzuki Fumitaka, Tsubota Akihito, Suzuki Yoshiyuki, Saitoh Satoshi, Kobayashi Masahiro, Akuta Norio, Someya Takashi, Hosaka Tetsuya, Kobayashi Mariko, Sezaki Hitomi, Ikeda Kenji, Kumada Hiromitsu
Department of Gastroenterology, Toranomon Hospital, Tokyo, Japan.
Intervirology. 2004;47(1):19-25. doi: 10.1159/000076638.
We assessed whether sustained negativity for HCV-RNA over 24 or more months by long-term interferon (IFN) therapy correlates with eradication of HCV in patients with hepatitis C virus genotype 1b and high viral load or not.
The number of patients with HCV-genotype 1b and high viral load exceeding 1 Meq/ml who received 6 MU of natural IFN-alpha daily for 2-8 weeks, followed by three times/week for 16-22 weeks and negativity for HCV-RNA during IFN administration was 403. Forty-one of 403 patients received 6 MU of natural IFN-alpha three times/week for more than 18 months after the initial IFN therapy (long-term-IFN-group). Three hundred and two patients did not receive any IFN treatment for 6 months after the termination of the 6-month course (6-month-IFN-group). Sustained virological response (SVR) was defined as negative HCV-RNA at both 3 and 6 months after the completion of IFN therapy.
SVR was noted in 73.2% (30/41) of long-term-IFN-group and 18.2% (55/302) of 6-month-IFN-group. Multivariate analysis showed that long-term IFN therapy was the most significant contributor to SVR (p < 0.0001).
Sustained negativity of HCV-RNA for 24 or more months by long-term IFN therapy correlated with SVR in patients with genotype 1b and high viral load.
我们评估了长期干扰素(IFN)治疗24个月及以上时丙型肝炎病毒RNA持续阴性与丙型肝炎病毒1b型且病毒载量高的患者中丙型肝炎病毒根除之间是否存在关联。
丙型肝炎病毒1b型且病毒载量超过1百万国际单位/毫升的患者,先每日接受6百万单位天然α干扰素治疗2 - 8周,随后每周三次治疗16 - 22周,且在干扰素治疗期间丙型肝炎病毒RNA呈阴性,此类患者有403例。403例患者中有41例在初始干扰素治疗后每周三次接受6百万单位天然α干扰素治疗超过18个月(长期干扰素组)。302例患者在6个月疗程结束后6个月未接受任何干扰素治疗(6个月干扰素组)。持续病毒学应答(SVR)定义为干扰素治疗结束后3个月和6个月时丙型肝炎病毒RNA均为阴性。
长期干扰素组中73.2%(30/41)出现SVR,6个月干扰素组中18.2%(55/302)出现SVR。多因素分析显示长期干扰素治疗是SVR的最主要影响因素(p < 0.0001)。
长期干扰素治疗使丙型肝炎病毒RNA持续阴性24个月及以上与1b型且病毒载量高的患者的SVR相关。